Free shipping on all orders over $ 500

Adalimumab

Cat. No. M6222
Adalimumab Structure
Synonym:

LU200134, D2E7, Anti-Human TNF-alpha

Size Price Availability Quantity
5mg USD 670  USD670 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).

In vivo: Adalimumab is safe and well tolerated. In healthy adults, the average absolute bioavailability of adalimumab 40 mg administered subcutaneously (s.c.) is 64%. Concentrations in the synovial fluid are 31-96% of those of the serum. Maximum plasma concentrations occur at 131 (± 56) h, and the mean half-life is ∼ 2 weeks (range, 10-20 days). Adalimumab treatment attenuates the Ovalbumin(OVA)-induced increase in serum IgE, TH2 and TH1 derived inflammatory cytokines (IL-4 and IFN-γ, respectively) in bronchoalveolar lavage (BAL) fluid, suppresses recruitment of inflammatory cells in BAL fluid and lung, and inhibits BAL fluid neutrophilia. It also ameliorates goblet cell metaplasia and bronchial fibrosis.

Protocol (for reference only)
Cell Experiment
Cell lines Caco-2 BBE cells
Preparation method T-84 and Caco-2 cells grown on transwell inserts were primed with IFN-γ (2.5 and 5 ng/ml, respectively) for 24 h followed by treatment with TNF-α (5 ng/ml), adalimumab (10 μg/ ml), or both.
Concentrations 10 μg/ ml
Incubation time 24 h
Animal Experiment
Animal models CD1 mice
Formulation PBS
Dosages 1 ml/100 g b.wt
Administration i.p.
Chemical Information
CAS Number 331731-18-1
Storage Store at -20°C or -70°C. Avoid multiple freeze-thaws.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jacks SM, et al. J Am Acad Dermatol. Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab.

[2] Fischer A, et al. Am J Physiol Gastrointest Liver Physiol. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.

Related TNF Receptor Products
APVO603

APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

STAR-0310

STAR-0310 is a novel OX40 antagonistic monoclonal antibody which has a potential best-in-class profile with a high affinity, potential for favorable safety and tolerability profile with low T cell depletion from ADCC or possible on-target cellular toxicity.

FS120

FS120 is a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4). FS120 has the potential to show activity in "cold" tumors and improve outcomes of existing immunotherapies by simultaneously agonizing CD137 and OX40.

ATOR-1015

ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. ATOR-1015 induces T-cell activation and Treg depletion in vitro.

YH002

YH002 is a recombinant anti-OX40 (CD134, TNFRSF4) humanized IgG1 agonistic antibody.

  Catalog
Abmole Inhibitor Catalog




Keywords: Adalimumab, LU200134, D2E7, Anti-Human TNF-alpha supplier, TNF Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.